Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.11. | McDonald's E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault | 3 | The Deep Dive | ||
11.11. | Cytophage Technologies Ltd: Cytophage Technologies talks R&D work for AviPhage | 1 | Stockwatch | ||
11.11. | Cytophage Technologies Ltd.: Cytophage Highlights Existing Phage Solutions to Recent Harmful Bacteria Outbreaks in Food Systems | 1 | TheNewswire | ||
05.11. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 05.11.2024 | 389 | Xetra Newsboard | The following instruments on XETRA do have their first trading 05.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.11.2024
Aktien
1 CA13740E1079 Cancambria Energy Corp.
2... ► Artikel lesen | |
04.10. | Cytophage Technologies Ltd.: Cytophage CEO to Discuss Reshaping Healthcare Through Phage Therapies During 2024 Canada SynBio Conference | 6 | TheNewswire | ||
29.08. | Cytophage Technologies Ltd: Cytophage's June 30 cash at $3.65-million | 1 | Stockwatch | ||
28.08. | Cytophage Technologies reports Q2 results | 1 | Seeking Alpha | ||
28.08. | Cytophage Technologies Ltd.: Cytophage Reports Q2 Financials including Business Update for First Half of 2024 | 1 | TheNewswire | ||
CYTOPHAGE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
15.08. | Cytophage Technologies Ltd: Cytophage rolls out lyophilized tablets for poultry | 1 | Stockwatch | ||
15.08. | Cytophage Develops Freeze-Dried Phage Tablets For Poultry | 1 | The Deep Dive | ||
15.08. | Phage Therapy's Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault | 1 | The Deep Dive | ||
15.08. | Cytophage Technologies Ltd.: Cytophage Launches Ready-to-Use Lyophilized Phage Tablets to Improve Gut Health in Poultry | 1 | TheNewswire | ||
27.06. | Cytophage Technologies Ltd: Cytophage holders approve all matters at AGM | 1 | Stockwatch | ||
27.06. | Cytophage Technologies Ltd.: Cytophage Reports AGM Results and Announces Upcoming Investor Call | 1 | TheNewswire | ||
21.06. | Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company | 1 | The Deep Dive | ||
20.06. | Cytophage Technologies Ltd: Cytophage to conduct trials with Asian poultry co. Q4 | 1 | Stockwatch | ||
20.06. | Cytophage Technologies Ltd.: Cytophage Expands Commercialization of Phage Products in Asian Poultry Market | 1 | TheNewswire | ||
04.06. | Cytophage Technologies Ltd.: Cytophage CEO to Present at TEDx Winnipeg Event | 1 | TheNewswire | ||
30.05. | Cytophage Technologies Ltd: Cytophage's March 31 cash at $5.56-million | 1 | Stockwatch | ||
30.05. | Cytophage Technologies Ltd.: Cytophage Reports Q1 Financials and Provides Business Update | 1 | TheNewswire |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,500 | -15,59 % | Evotec: Jetzt ist hier wieder richtig Pfeffer drin | Es ist ein Klassiker: Ein vorher vielversprechendes Unternehmen strauchelt, der Aktienkurs bricht ein - und dadurch wird das Unternehmen zu einem lukrativen Ziel für Konkurrenten und Großinvestoren.... ► Artikel lesen | |
QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
BIONTECH | 108,90 | +0,28 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
DYNE THERAPEUTICS | 29,690 | -0,27 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
MODERNA | 39,575 | +0,18 % | Dicke Kurschance: Biontech oder Moderna: Welche Aktie ist besser für die mRNA-Revolution? | © Foto: Gorodenkoff / Stock.adobe.comDie Investmentbank Berenberg nimmt die Aktien der führenden mRNA-Unternehmen BioNTech und Moderna unter die Lupe. Die Analysten haben einen klaren Favoriten.Mit... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |